Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Industry Analysis and Forecast (2019-2026): By Drug Type, Distribution Channel And Region.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market size is expected to grow from US$ XXBn in 2019 to USD XX Bn by 2026, at a CAGR of 4.1% during the forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology   :- Request Free Sample Report Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. Exposure to second-hand or passive smoking. Smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and incidence of respiratory diseases i.e., asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market. New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments. Rise in number of public and private organizations is another major factor propelling the growth of COPD Treatment market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market in developing regions, thereby boosting overall market growth. There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth. By drug type, bronchodilators are further categorized as Short-Acting Bronchodilators and Long- Acting Bronchodilators. These medications work quickly to relax the muscles around your airways and ease symptoms like coughing and shortness of breath. The effects last for about 6 to 12 hours. North America dominates Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market because of rise in collaborations and high investments in healthcare sector. Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults. The objective of the report is to present comprehensive analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding  dynamics, structure by analyzing the market segments, and project the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market make the report investor’s guide.

Scope of the Chronic Obstructive Pulmonary Disease (COPD) Treatment market: Inquire before buying

Chronic Obstructive Pulmonary Disease (COPD) Treatment market  by Drug type

• combination, • bronchodilators, • corticosteroids, • phosphodiesterase type 4 inhibitors, • mucokineticsm

Chronic Obstructive Pulmonary Disease (COPD) Treatment market by Distribution channel,

• hospital pharmacies, • retail pharmacies, • online pharmacies.

Chronic Obstructive Pulmonary Disease (COPD) Treatment market By Region

• Asia-Pacific • Europe • North America • Middle East & Africa • South America

Key players Chronic Obstructive Pulmonary Disease (COPD) Treatment market

• AstraZeneca, • Boehringer Ingelheim Pharmaceuticals, Inc., • GlaxoSmithKline plc, • Novartis AG, • CHIESI Farmaceutici S.p.A., • Sunovion Pharmaceuticals, Inc. • Teva Pharmaceutical Industries Ltd, • Mylan N.V. • Orion Corporation. • Abbott • Dr. Reddy's Laboratories Ltd • F. Hoffmann-La Roche Ltd • Forest Labs • GSK • Galapagos NV • Merck • Mundipharma • Nycomed • Orexo • Pfizer Inc • Roche
Chronic Obstructive Pulmonary Disease (COPD) Treatment market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast 6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, By Drug type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, By Drug type 7.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, By Drug type 7.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, By Drug type 8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, By Distribution channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 8.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, By Distribution channel 8.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, By Distribution channel 8.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, By Distribution channel 9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Region 9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region 9.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Bn) Forecast, by Region 9.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region 10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis 10.1. Key Findings 10.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview 10.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 10.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 10.4.1. combination, 10.4.2. bronchodilators, 10.4.3. corticosteroids, 10.4.4. phosphodiesterase type 4 inhibitors, 10.4.5. mucokineticsm 10.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 10.6. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 10.6.1. hospital pharmacies, 10.6.2. retail pharmacies, 10.6.3. online pharmacies 10.7. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country 10.8. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country 10.10. U.S. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 10.10.1. combination, 10.10.2. bronchodilators, 10.10.3. corticosteroids, 10.10.4. phosphodiesterase type 4 inhibitors, 10.10.5. mucokineticsm 10.11. U.S. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 10.11.1. hospital pharmacies, 10.11.2. retail pharmacies, 10.11.3. online pharmacies 10.12. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 10.12.1. combination, 10.12.2. bronchodilators, 10.12.3. corticosteroids, 10.12.4. phosphodiesterase type 4 inhibitors, 10.12.5. mucokineticsm 10.13. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 10.13.1. hospital pharmacies, 10.13.2. retail pharmacies, 10.13.3. online pharmacies 10.14. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 10.14.1. By Drug type 10.14.2. By Distribution channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis 11.1. Key Findings 11.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview 11.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 11.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.4.1. combination, 11.4.2. bronchodilators, 11.4.3. corticosteroids, 11.4.4. phosphodiesterase type 4 inhibitors, 11.4.5. mucokineticsm 11.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 11.6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.6.1. hospital pharmacies, 11.6.2. retail pharmacies, 11.6.3. online pharmacies 11.7. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country 11.8. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country 11.10. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.10.1. combination, 11.10.2. bronchodilators, 11.10.3. corticosteroids, 11.10.4. phosphodiesterase type 4 inhibitors, 11.10.5. mucokineticsm 11.11. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.11.1. hospital pharmacies, 11.11.2. retail pharmacies, 11.11.3. online pharmacies 11.12. U.K. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.12.1. combination, 11.12.2. bronchodilators, 11.12.3. corticosteroids, 11.12.4. phosphodiesterase type 4 inhibitors, 11.12.5. mucokineticsm 11.13. U.K. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.13.1. hospital pharmacies, 11.13.2. retail pharmacies, 11.13.3. online pharmacies 11.14. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.14.1. combination, 11.14.2. bronchodilators, 11.14.3. corticosteroids, 11.14.4. phosphodiesterase type 4 inhibitors, 11.14.5. mucokineticsm 11.15. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.15.1. hospital pharmacies, 11.15.2. retail pharmacies, 11.15.3. online pharmacies 11.16. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.16.1. combination, 11.16.2. bronchodilators, 11.16.3. corticosteroids, 11.16.4. phosphodiesterase type 4 inhibitors, 11.16.5. mucokineticsm 11.17. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.17.1. hospital pharmacies, 11.17.2. retail pharmacies, 11.17.3. online pharmacies 11.18. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.18.1. combination, 11.18.2. bronchodilators, 11.18.3. corticosteroids, 11.18.4. phosphodiesterase type 4 inhibitors, 11.18.5. mucokineticsm 11.19. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.19.1. hospital pharmacies, 11.19.2. retail pharmacies, 11.19.3. online pharmacies 11.20. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 11.20.1. combination, 11.20.2. bronchodilators, 11.20.3. corticosteroids, 11.20.4. phosphodiesterase type 4 inhibitors, 11.20.5. mucokineticsm 11.21. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 11.21.1. hospital pharmacies, 11.21.2. retail pharmacies, 11.21.3. online pharmacies 11.22. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 11.22.1. By Drug type 11.22.2. By Distribution channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis 12.1. Key Findings 12.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview 12.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 12.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.4.1. combination, 12.4.2. bronchodilators, 12.4.3. corticosteroids, 12.4.4. phosphodiesterase type 4 inhibitors, 12.4.5. mucokineticsm 12.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 12.6. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.6.1. hospital pharmacies, 12.6.2. retail pharmacies, 12.6.3. online pharmacies 12.7. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country 12.8. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country 12.10. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.10.1. combination, 12.10.2. bronchodilators, 12.10.3. corticosteroids, 12.10.4. phosphodiesterase type 4 inhibitors, 12.10.5. mucokineticsm 12.11. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.11.1. hospital pharmacies, 12.11.2. retail pharmacies, 12.11.3. online pharmacies 12.12. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.12.1. combination, 12.12.2. bronchodilators, 12.12.3. corticosteroids, 12.12.4. phosphodiesterase type 4 inhibitors, 12.12.5. mucokineticsm 12.13. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.13.1. hospital pharmacies, 12.13.2. retail pharmacies, 12.13.3. online pharmacies 12.14. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.14.1. combination, 12.14.2. bronchodilators, 12.14.3. corticosteroids, 12.14.4. phosphodiesterase type 4 inhibitors, 12.14.5. mucokineticsm 12.15. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.15.1. hospital pharmacies, 12.15.2. retail pharmacies, 12.15.3. online pharmacies 12.16. ASEAN Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.16.1. combination, 12.16.2. bronchodilators, 12.16.3. corticosteroids, 12.16.4. phosphodiesterase type 4 inhibitors, 12.16.5. mucokineticsm 12.17. ASEAN Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.17.1. hospital pharmacies, 12.17.2. retail pharmacies, 12.17.3. online pharmacies 12.18. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 12.18.1. combination, 12.18.2. bronchodilators, 12.18.3. corticosteroids, 12.18.4. phosphodiesterase type 4 inhibitors, 12.18.5. mucokineticsm 12.19. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 12.19.1. hospital pharmacies, 12.19.2. retail pharmacies, 12.19.3. online pharmacies 12.20. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 12.20.1. By Drug type 12.20.2. By Distribution channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview 13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 13.4.1. combination, 13.4.2. bronchodilators, 13.4.3. corticosteroids, 13.4.4. phosphodiesterase type 4 inhibitors, 13.4.5. mucokineticsm 13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 13.6. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 13.6.1. hospital pharmacies, 13.6.2. retail pharmacies, 13.6.3. online pharmacies 13.7. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country 13.8. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis, by Country 13.10. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 13.10.1. combination, 13.10.2. bronchodilators, 13.10.3. corticosteroids, 13.10.4. phosphodiesterase type 4 inhibitors, 13.10.5. mucokineticsm 13.11. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 13.11.1. hospital pharmacies, 13.11.2. retail pharmacies, 13.11.3. online pharmacies 13.12. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 13.12.1. combination, 13.12.2. bronchodilators, 13.12.3. corticosteroids, 13.12.4. phosphodiesterase type 4 inhibitors, 13.12.5. mucokineticsm 13.13. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 13.13.1. hospital pharmacies, 13.13.2. retail pharmacies, 13.13.3. online pharmacies 13.14. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 13.14.1. combination, 13.14.2. bronchodilators, 13.14.3. corticosteroids, 13.14.4. phosphodiesterase type 4 inhibitors, 13.14.5. mucokineticsm 13.15. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 13.15.1. hospital pharmacies, 13.15.2. retail pharmacies, 13.15.3. online pharmacies 13.16. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 13.16.1. By Drug type 13.16.2. By Distribution channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis 14.1. Key Findings 14.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview 14.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Drug type 14.4. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 14.4.1. combination, 14.4.2. bronchodilators, 14.4.3. corticosteroids, 14.4.4. phosphodiesterase type 4 inhibitors, 14.4.5. mucokineticsm 14.5. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, By Distribution channel 14.6. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 14.6.1. hospital pharmacies, 14.6.2. retail pharmacies, 14.6.3. online pharmacies 14.7. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country 14.8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 14.9.1. combination, 14.9.2. bronchodilators, 14.9.3. corticosteroids, 14.9.4. phosphodiesterase type 4 inhibitors, 14.9.5. mucokineticsm 14.10. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 14.10.1. hospital pharmacies, 14.10.2. retail pharmacies, 14.10.3. online pharmacies 14.11. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 14.11.1. combination, 14.11.2. bronchodilators, 14.11.3. corticosteroids, 14.11.4. phosphodiesterase type 4 inhibitors, 14.11.5. mucokineticsm 14.12. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 14.12.1. hospital pharmacies, 14.12.2. retail pharmacies, 14.12.3. online pharmacies 14.13. Rest of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Drug type 14.13.1. combination, 14.13.2. bronchodilators, 14.13.3. corticosteroids, 14.13.4. phosphodiesterase type 4 inhibitors, 14.13.5. mucokineticsm 14.14. Rest of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast, By Distribution channel 14.14.1. hospital pharmacies, 14.14.2. retail pharmacies, 14.14.3. online pharmacies 14.15. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis 14.15.1. By Drug type 14.15.2. By Distribution channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Drug type Launches and Drug type Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. AstraZeneca 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Drug type Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Boehringer Ingelheim Pharmaceuticals, Inc., 15.3.3. GlaxoSmithKline plc, 15.3.4. Novartis AG, 15.3.5. CHIESI Farmaceutici S.p.A., 15.3.6. Sunovion Pharmaceuticals, Inc. 15.3.7. Sumitomo Dainippon Pharma Co., Ltd, 15.3.8. Teva Pharmaceutical Industries Ltd, 15.3.9. Mylan N.V., 15.3.10. Orion Corporation. 15.3.11. Abbott 15.3.12. Dr. Reddy's Laboratories Ltd 15.3.13. F. Hoffmann-La Roche Ltd 15.3.14. Forest Labs 15.3.15. GSK 15.3.16. Galapagos NV 15.3.17. Merck 15.3.18. Mundipharma 15.3.19. Nycomed 15.3.20. Orexo 15.3.21. Pfizer Inc 15.3.22. Roche 16. Primary Key Insights

About This Report

Report ID 35981
Category Healthcare
Published Date Nov 2019
Updated Date Oct 2020
Contact Us